Etiology of cirrhosis is associated with risk of hepatic decompensation and hepatocellular carcinoma.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
1029 patients (median age 58 years, 54.
I · Intervention 중재 / 시술
transplant, and 23
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
[BACKGROUND] The impact of the changing epidemiology from viral to non-viral etiologies of cirrhosis on the burden of liver-related complications remains unclear.
- 95% CI 0.94 - 2.45
- 추적기간 84.7 months
- 연구 설계 cohort study
APA
Ng M, Bardhi O, et al. (2025). Etiology of cirrhosis is associated with risk of hepatic decompensation and hepatocellular carcinoma.. BMC gastroenterology, 26(1), 22. https://doi.org/10.1186/s12876-025-04538-y
MLA
Ng M, et al.. "Etiology of cirrhosis is associated with risk of hepatic decompensation and hepatocellular carcinoma.." BMC gastroenterology, vol. 26, no. 1, 2025, pp. 22.
PMID
41366647 ↗
Abstract 한글 요약
[BACKGROUND] The impact of the changing epidemiology from viral to non-viral etiologies of cirrhosis on the burden of liver-related complications remains unclear.
[METHODS] We conducted a retrospective cohort study of adult patients with cirrhosis and an index outpatient visit between January and December 2015 at two U.S. health systems. We excluded patients with a history of hepatocellular carcinoma (HCC) or both prevalent ascites and hepatic encephalopathy. Fine-Gray sub-distribution hazard models were used to characterize time-to-incident hepatic decompensation and incident HCC through 2020, with liver transplantation and death as competing events, and multivariable Fine-Gray regression was used to identify associated factors.
[RESULTS] We identified 1029 patients (median age 58 years, 54.9% male, 19.5% non-Hispanic White). Over a median follow-up of 84.7 months, 36.4% developed incident hepatic decompensation (46.7% ascites, 21.1% hepatic encephalopathy, and 32.3% ascites plus hepatic encephalopathy), 14.5% developed HCC, 2.0% underwent transplant, and 23.0% died. The cumulative 1-, 2-, and 3-year incidence of hepatic decompensation were 7.0%, 10.8%, and 16.3% and incidence of HCC were 3.0%, 5.0%, and 6.9%, respectively. Compared to viremic hepatitis C, higher risk of hepatic decompensation was associated with metabolic dysfunction-associated steatotic liver disease (MASLD) (sHR 1.52, 95% CI 0.94 - 2.45) and alcohol-associated cirrhosis (sHR 1.68, 95%CI 1.10 - 2.57), while incident HCC was inversely associated with MASLD (sHR 0.27; 95% CI 0.12-0.59) and alcohol-associated cirrhosis (sHR 0.45; 95% CI 0.23-0.84).
[CONCLUSION] Increasing proportions of non-viral liver disease will likely lead to a greater burden of hepatic decompensation and reduced HCC in contemporary populations.
[METHODS] We conducted a retrospective cohort study of adult patients with cirrhosis and an index outpatient visit between January and December 2015 at two U.S. health systems. We excluded patients with a history of hepatocellular carcinoma (HCC) or both prevalent ascites and hepatic encephalopathy. Fine-Gray sub-distribution hazard models were used to characterize time-to-incident hepatic decompensation and incident HCC through 2020, with liver transplantation and death as competing events, and multivariable Fine-Gray regression was used to identify associated factors.
[RESULTS] We identified 1029 patients (median age 58 years, 54.9% male, 19.5% non-Hispanic White). Over a median follow-up of 84.7 months, 36.4% developed incident hepatic decompensation (46.7% ascites, 21.1% hepatic encephalopathy, and 32.3% ascites plus hepatic encephalopathy), 14.5% developed HCC, 2.0% underwent transplant, and 23.0% died. The cumulative 1-, 2-, and 3-year incidence of hepatic decompensation were 7.0%, 10.8%, and 16.3% and incidence of HCC were 3.0%, 5.0%, and 6.9%, respectively. Compared to viremic hepatitis C, higher risk of hepatic decompensation was associated with metabolic dysfunction-associated steatotic liver disease (MASLD) (sHR 1.52, 95% CI 0.94 - 2.45) and alcohol-associated cirrhosis (sHR 1.68, 95%CI 1.10 - 2.57), while incident HCC was inversely associated with MASLD (sHR 0.27; 95% CI 0.12-0.59) and alcohol-associated cirrhosis (sHR 0.45; 95% CI 0.23-0.84).
[CONCLUSION] Increasing proportions of non-viral liver disease will likely lead to a greater burden of hepatic decompensation and reduced HCC in contemporary populations.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.